EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Friday, July 19th 2019 at 12:30pm UTC FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global …
Plus »Acerus Announces Closing of US$5 Million Secured Term Loan
Friday, July 19th 2019 at 11:00am UTC TORONTO–(BUSINESS WIRE)– Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million subordinated secured term loan facility (“the Loan”) with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of the …
Plus »Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter Into a Clinical Collaboration Agreement to Investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as Combination Therapy in Patients With Metastatic Colorectal Cancer
Thursday, July 18th 2019 at 10:30am UTC Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer Companies plan indication-seeking trial WHIPPANY, N.J. & PRINCETON, N.J. & OSAKA, Japan–(BUSINESS WIRE)– Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., …
Plus »Certara Expands Its Drug Evidence & Access Capabilities Through the Addition of Compass Strategic Consulting’s Team
Thursday, July 18th 2019 at 12:00pm UTC The strategic expansion of Certara’s US Access practice provides clients with opportunities to confront increasing drug pricing and reimbursement challenges PRINCETON, N.J.–(BUSINESS WIRE)– Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that the …
Plus »Inflection Biosciences and AUM Biosciences Announce Global License Agreement for PIM/PI3K/mTOR Inhibitors
Thursday, July 18th 2019 at 6:00am UTC DUBLIN–(BUSINESS WIRE)– Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of cancer, and AUM Biosciences (AUM), a company focused on the development of innovative and affordable oncology medicines with high unmet medical need in Asia, today announced a global license …
Plus »Lonza choisit Rockwell Automation pour la transformation numérique de ses opérations pharmaceutiques
Tuesday, July 16th 2019 at 3:19pm UTC Lonza utilisera le logiciel PharmaSuite MES, ainsi que FactoryTalk InnovationSuite pour accélérer la production sans papier 24h/24 et 7j/7 de capsules de pointe MILWAUKEE–(BUSINESS WIRE)– Lonza a choisi Rockwell Automation pour la mise en œuvre clé en main de sa vision stratégique consistant …
Plus »Cyclica and University of Toronto Stagljar Lab Announce Partnership to Create the Next-Generation EGFR Inhibitors in Non-Small Cell Lung Cancer
Tuesday, July 16th 2019 at 1:30pm UTC TORONTO–(BUSINESS WIRE)– Cyclica, a Toronto-based biotechnology company leveraging AI and computational biophysics for drug discovery, and Professor Igor Stagljar from the Donnelly Centre for Cellular and Biomolecular Research, Department of Biochemistry & Department of Molecular Genetics at the University of Toronto, announce a …
Plus »Optimal Just-in-Time Service Changing the Paradigm of Cancer Trials
Tuesday, July 16th 2019 at 1:00pm UTC First-patient-in milestone achieved in only two weeks with Cancer Treatment Centers of America WILMINGTON, N.C.–(BUSINESS WIRE)– Optimal Just-in-Time, a service of PPD’s Accelerated Enrollment Solutions (AES) business unit, and Cancer Treatment Centers of America® (CTCA) are collaborating to speed patient enrollment in oncology …
Plus »Gotham Therapeutics and Mercachem Announce Progress in Compound Library Development Tailored for Epitranscriptomic Drug Discovery
Wednesday, July 17th 2019 at 7:00am UTC Research led to a collection of over 2,000 analogues and over 80 distinct chemotypes displaying an up to 1,000-fold increased affinity to epitranscriptomic targets NEW YORK & NIJMEGEN, Netherlands–(BUSINESS WIRE)– Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, …
Plus »Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss
Wednesday, July 17th 2019 at 7:00am UTC Astellas Obtains the Exclusive Rights to Develop and Commercialize FX-322 in Ex-U.S. Markets; Frequency Retains U.S. Rights Frequency will Receive $80 Million Upfront from Astellas with the Potential of up to $545 Million in Future Milestone Payments as well as Double-Digit Royalties TOKYO …
Plus »
